CanSino Biologics (688185.SH, 06185.HK)

Executive Summary

CanSino Biologics is a Chinese vaccine developer leveraging its proprietary adenovirus vector platform (Ad5) to create vaccines for infectious diseases. The company gained global recognition with its COVID-19 vaccine, Convidecia, which was widely deployed in China and exported to multiple countries. However, declining COVID-19 vaccine demand has pressured revenues, prompting CanSino to pivot toward a diversified pipeline targeting tuberculosis, meningococcal disease, pneumococcal disease, and pertussis. Its lead candidate, a tuberculosis vaccine (Ad5-EBOV-based), is in late-stage trials and could address a significant global unmet need. Additionally, the company is developing an inhaled version of its COVID-19 vaccine to differentiate in the booster market. Despite manufacturing scale and established distribution, CanSino faces intense competition from mRNA and viral vector vaccines, as well as regulatory hurdles in overseas markets. Financial sustainability remains a concern, but the company's strong R&D capabilities and partnership with the Chinese government provide a buffer. Key upcoming catalysts include pivotal trial data for the tuberculosis vaccine, potential approval of the inhaled COVID-19 vaccine in China, and expansion of its meningococcal vaccine franchise. The stock's performance will likely hinge on pipeline progress and execution in non-COVID indications.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 data readout for tuberculosis vaccine (Ad5-EBOV)40% success
• Q3 2026Approval of inhaled COVID-19 booster in China70% success
• Q4 2026Meningococcal conjugate vaccine approval in emerging markets60% success